Menu
Menu
SOPHiA GENETICS is thrilled to attend this year's Association for Molecular Pathology (AMP) Annual Meeting at the Seattle Convention Center!
Find us at Booth #715 to explore how SOPHiA DDM™ is advancing precision oncology across comprehensive solid tumor profiling and hematologic malignancies, with AI-powered analytics that transform complex data into actionable insights.
Corporate Workshop: One Integrated Workflow from Tissue to Liquid Biopsy: Real-World Insights on MSK-IMPACT® Flex and MSK-ACCESS® powered with SOPHiA DDM™
Wednesday, November 11 – 8:00 AM – 8:50 AM
Skagit 5, Lower Level, Arch at 800 Pike
Speakers:
Andrew Fellowes – Lead Scientist, Molecular Diagnostic Development, Peter MacCallum Cancer Center
Lina Li, Product Marketing Director – Solid Tumors, SOPHiA GENETICS
Corporate Workshop: Scaling Decentralized Pan-Cancer Liquid Biopsy: Multicentric Validation of MSK-ACCESS® powered with SOPHiA DDM™
Wednesday, November 11 – 9:00 AM – 9:50 AM
Skagit 5, Lower Level, Arch at 800 Pike
Speaker:
Florian Klemm, Technical Product Management Expert, SOPHiA GENETICS
Blood Cancer Showcase: The Next Frontier in Blood Cancer Genomics
Wednesday, November 11 – 6:30 PM
Venue TBD, Seattle
Join SOPHiA GENETICS for an evening, dedicated to advances in blood cancer, diagnostics, and precision oncology.
Agenda:
Brandon Bullough - Product Marketing Director, Blood Cancers, SOPHiA GENETICS
Gang Zheng, M.D., Ph.D. - Co-director Clinical Genomics Laboratory, Professor of Laboratory Medicine and Pathology, Mayo Clinic
Todd C. Knepper, PharmD - Associate Member in Precision Oncology, Department of Pathology, Moffitt Cancer Center
Poster Presentations
Saturday, November 14 – 9:15 – 10:15 AM
Presenter: Florian Klemm, Technical Product Management Expert, SOPHiA GENETICS
Co-authors: Fuad Mohammad, Jonathan Bieler, Frederic Michaud, Anjali Anjali, Alex Charles Tuck, Saraj Figarol, Anne Pradines, Laura Keller, Maryline Allegra, Guylene Rignol, Paul Hofman, Caroline Lacoux, Laurie Canetti, Emeline Jorge, Frédérique Penault-Llorca, Marie-Celeste Ferreira, Rochelle Awuku, Alasdair Heasman, Gareth Gerrard, Persephone Du-Parcq, Gaëlle Lescuyer, Marie Piecyk, Lea Payen, Tessara Baldi, Anita Bowman, Rose Brannon, Michael Berger, Zhenyu Xu
Presenter: Slawomir Kubik, Head of Technical Product Management – Oncology, SOPHiA GENETICS
Co-authors: Christian Pozzorini, Alexis Bachmann, Gregoire Andre, Frederic Michaud, Elia Magrinelli, Tommaso Coletta, Yvan Wenger, Adrian Willig, Kevin Green, Benjamin Krajacich, Marina McCowin, Kelly Wiseman, Junhua Zhao, Zhenyu Xu
Plan your AMP visit
Whether you're working in solid tumor profiling, liquid biopsy, or hematologic malignancies, we'd love to connect and learn more about the challenges your laboratory is working to solve.
Meeting slots at AMP fill quickly. Book time with our team before you arrive in Seattle.
See you there! 🧬
📍 National Institutes of Health (NIH), Kuala Lumpur, Malaysia | ⏱️ 2-hour session (10am - 12pm) | 8 October 2026
An exclusive educational session for government laboratory specialists, bioinformaticians, and pathologists
About This Session
As genomic testing volumes continue to rise across public healthcare systems, laboratories are under increasing pressure to deliver faster, more consistent, and more clinically actionable results.
SOPHiA GENETICS, in partnership with Science Vision, invites government stakeholders at the forefront of genomic diagnostics in Malaysia to a dedicated educational session, offering a substantive discussion of the analytical and interpretive challenges facing genomic laboratories today, and how AI-powered platforms such as SOPHiA DDM™ are helping address them.
Participants will gain practical insight into modern genomic workflows, observe the platform in a live demonstration, and have the opportunity to contribute their own laboratory's challenges to the discussion.
Why Attend
Agenda
| Agenda |
|---|
| Welcome & Stakeholder Introductions |
| How SOPHiA DDM™ Tackles Real-World Genomic Challenges |
| Live Platform Demo — See SOPHiA DDM™ in action, from sample to report |
| User Experience Sharing |
| Open Discussion & Q&A |
Who Should Attend
Government laboratory specialists, bioinformaticians, pathologists, and public healthcare stakeholders involved in genomic testing and analysis.
Copy number variants (CNVs) are increasingly recognized as clinically significant biomarkers across a wide range of tumor types, with emerging evidence supporting their role in prognosis, therapeutic stratification, and disease characterization. Despite advances in CGP, accurate CNV detection and interpretation in solid tumors remains challenging, owing to tumor heterogeneity, assay complexity, and inconsistent analytical approaches.
In this webinar, participants will explore current challenges and considerations associated with CNV detection and interpretation in precision oncology research. Through real-world examples and discussion of CGP strategies, the webinar will examine approaches for improving scalability, consistency, and confidence in biomarker characterization.
Join us to gain insight into evolving approaches for CGP and the role of CNV analysis in advancing precision oncology research.
At the conclusion of this session, participants will be able to:
Presenter
Dr. Rami Mahfouz MD, MPH, IFCAP
Professor of Molecular Pathology, Head of Division of Clinical Pathology, Director of Molecular Diagnostics Laboratory, American University of Beirut, Lebanon
Dr. Lina Li, PhD, MBA
Director of Product for Solid Tumors, SOPHiA GENETICS
Evidence-based interpretation of oncogenic variants represents one of the most demanding and time-consuming tasks carried out by clinical laboratories today. The volume of emerging clinical evidence,and the multiplication of evidence sources across fragmented platforms, combined with the need fortimely and accurate reporting, places considerable pressure on laboratory workflows and the professionals who lead them.
In this webinar, Dr. Sara Allegrini, Head of Molecular Pathology at TomaLab, one of the largest genetic laboratories in Italy, examines how the integration of OncoPortal™ Knowledge Base within SOPHiADDM™ has reshaped their approach to oncology variant interpretation. The session draws on Dr.Allegrini's real-world experience to trace the laboratory's workflow evolution, from their previous use of OncoPortal™ Plus as a standalone module to the adoption of a fully integrated solution.
Dr. Allegrini will share first-hand insights into the challenges of evidence-based interpretation at scale,the criteria that guided TomaLab's adoption of OncoPortal™ Knowledge Base, and the impact observedon reporting efficiency and interpretation confidence. The session will also illustrate the value of the platform through concrete case examples, including rare alterations and complex findings where accessto curated, current evidence proved decisive.
At the conclusion of this session, participants will be able to:
Presenter
Dr. Sara Allegrini, Molecular Biologist, Leading the Somatic Molecular Diagnostics Unit at a specialized pathology laboratory
Dr. Sara Allegrini is a molecular biologist and expert in precision oncology, currently leading the Somatic Molecular Diagnostics Unit at a specialized pathology laboratory. With over a decade of experience in molecular diagnostics and cancer genomics, she plays a key role in integrating advanced technologies such as next-generation sequencing into routine clinical practice.
She holds a PhD in Molecular Medicine and a specialization in Clinical Pathology, complemented by a recent advanced Master’s degree in Molecular Pathology and Molecular Tumor Boards. Her expertise spans next-generation sequencing, molecular oncology, and precision medicine, with a strong focus on the interpretation of somatic variants in cancer. Her work focuses on the clinical interpretation of somatic variants and their application in personalized cancer treatment.
She has a strong background in translational research, bridging the gap between laboratory innovation and patient care. She is passionate about advancing precision medicine and improving diagnostic strategies in oncology.
June 3, 2026 | 1:00PM SGT
Clinical Genomics at MSK
Michael Berger, Ph.D
Co-Director, Marie Josee & Henry Kravis Center for Molecular Oncology, MSKCC
Dr. Berger’s session will explore the development of MSK-IMPACT and MSK-ACCESS, MSK’s comprehensive genomic profiling andcfDNA analysis programs. These initiatives address the need for large-scale molecular profiling across diverse tumor types. A keyfocus will be the role of matched tumor-normal sequencing in reducing biological false positives, ensuring true somatic variantsare accurately identified while enabling seamless integration of germline analysis. Dr. Berger will also discuss how SOPHiAGENETICS has become a key collaborator, empowering MSK to expand the accessibility of precision oncology globally throughscalable, cloud-based solutions.
Advancing Precision Oncology with a Matched Tumor-Normal Approach: Insights from the Clinic
Anita Bowman, M.S,
Associate Director of Clinical Bioinformatics, MSKCC
Anita Bowman will delve into the clinical applications of MSK-IMPACT and MSK-ACCESS at MSK, illustrating how thesetechnologies meet the personalized needs of patients. Through real-world case studies, she will showcase how a matchedtumor-normal approach has enhanced diagnosis and treatment planning. This methodology not only minimizes false positivesbut also identifies clonal hematopoiesis of indeterminate potential (CHIP) and resistance mechanisms, improving precision intreatment strategies.
Learning Objectives
June 17, 2026 | 1:00PM SGT
Comprehensive genomic profiling (CGP) using a matched tumor-normal approach can help improve somatic detection rate and streamline interpretation.
MSK-IMPACT® powered with SOPHiA DDM™ is a CGP solution that leverages matched tumor-normal sequencing to filter germline variants and may also identify clonal hematopoietic variants, revealing mutations of true somatic origin. The end-to-end application combines the clinical expertise of Memorial Sloan Kettering Cancer Center (MSK) with the robust analytics of SOPHiA DDM™.
Join us and MSK to:
SOPHiA GENETICS will be at the Association for Molecular Pathology Europe Congress (AMP Europe) 2026 in Tallinn, Estonia. Find us at Booth #13 where our team of experts will be ready to discuss how SOPHiA DDM™ platform is helping laboratories and healthcare institutions advance data-driven oncology insights.
Come explore our partnership with the Memorial Sloan Kettering Cancer Center and our latest updates across the MSK solutions portfolio, including enhanced CNV detection with tumor purity and ploidy analysis in MSK-IMPACT® Flex, and new capabilities in MSK-ACCESS® including MSI and ctDNA fraction, now available on GEN2.
Also learn more about OncoKB™ which is now fully embedded in SOPHiA DDM™ oncology workflows, and what that means for somatic variant interpretation in practice.
Industry Symposium
Join our Industry Symposium to explore how combining MSK-IMPACT® Flex and MSK-ACCESS® on the SOPHiA DDM™ Platform unlocks deeper, more complete oncology insights. From real-world use cases to the latest liquid biopsy enhancements, this is a must-attend session for those looking to take their genomic profiling further.
Monday, 15 June | 2:30pm – 3:30pm | Ballroom
Integrating tissue and liquid biopsy for in-depth precision oncology insights
Dr. Maria De Bonis, Biologist and Health Manager, Fondazione Policlinico A. Gemelli IRCCS, Italy
Lina Li, Product Director of Solid Tumors, SOPHiA GENETICS
SOPHiA GENETICS is proud to participate in the Congreso Latinoamericano de Patología 2025, taking place in Santiago, Chile.
📍 Visit us at Booth S5
Our team will be on-site to showcase how SOPHiA GENETICS is transforming pathology and laboratory medicine with data-driven insights. Explore our latest innovations across Liquid Biopsy, Solid Tumors, Hematologic Malignancies, and more—empowering clinicians and researchers to advance precision medicine in Latin America.
We look forward to connecting with the pathology community in Santiago and sharing how our technology is shaping the future of healthcare.
Hosted by: SOPHiA GENETICS
Presented by: Alexandre Harlé
Professor of of Biopathology, Head of Precision Medicine and Translational Research Service, Institut de Cancérologie de Lorraine (ICL), France
As precision oncology advances, clinicians and researchers require solid tumor profiling tools that go beyond traditional approaches. While most next-generation sequencing (NGS) solutions rely on DNA as input, RNA sequencing provides unique molecular insights that can inform decision making, particularly from detecting gene fusions, exon skipping, and changes in gene expression. However, practical barriers such as limited tissue availability, complex workflows, and time-consuming interpretation can challenge laboratories implementing RNA sequencing.
In this webinar, Alexandre Harlé, professor and hospital practitioner, will provide an in-depth look at expertly designed RNA NGS solutions for advanced variant detection from solid tumors, including lung and sarcoma. Harlé will share his experience of co-developing and implementing in-house, sample-to-report solutions that address the current and future needs of the Cancer Institute of Lorraine in Nancy, France.
Learning objectives:
Discover the robust analytical performance of an innovative RNA technology that detects novel (partner-agnostic) gene fusions — even when fusion partners are unknown — as well as exon skipping events and gene expression changes from small input amounts. Explore how decentralized sample-to-report workflows with fully integrated analysis, interpretation, and reporting features help accelerate turnaround times and improve operational efficiency.
Understand the value of combining targeted RNA and DNA insights to capture a more comprehensive molecular picture to support informed decision-making.
Speaker Bio:
Professor Alexandre Harlé leads the Precision Medicine and Translational Research group at the Institut de Cancérologie de Lorraine (ICL), France. His research focuses on integrating RNA sequencing and liquid biopsy approaches to better understand tumor biology and improve patient care. He has contributed to collaborative efforts developing RNA-based signatures, such as GemPred, for predicting chemotherapy response in pancreatic cancer. His team is also involved in national studies exploring circulating tumor DNA (ctDNA) for minimal residual disease detection and longitudinal monitoring. Combining clinical expertise with advanced molecular techniques, Harlé’s work aims to support the implementation of precision oncology in routine practice.
Dr. Hemad Yasaei, Head of Molecular Genomics, National Reference Laboratory (NRL), Abu Dhabi
Comprehensive genomic profiling (CGP) of solid tumors has become an essential tool in guiding precision medicine approaches. As cancer research advances, clinical laboratories require fast, scalable, and accurate CGP technologies to detect both known and emerging biomarkers with confidence.
Through the decentralized and technology-agnostic SOPHiA DDM™ Platform, institutions worldwide can now benefit from MSK-IMPACT®, Memorial Sloan Kettering Cancer Center’s best-in-class CGP application. This innovative solution leverages matched tumor-normal sequencing to reveal variants of true somatic origin, delivering highly accurate research insights.
Join Dr. Hemad Yasaei, Head of Molecular Genomics at National Reference Laboratory, UAE, as he shares his experience of:
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.